Effector TherapeuticsEFTR
13F holders, Q1 2024 (March 31)15holders
$14.32avg. 13F price*
At the end of Q1 2024, 15 institutions reported holding Effector Therapeutics Inc. (EFTR) in their 13F filings. The largest holders were Armistice Capital, LLC ($3.2M), Carlyle Group Inc. ($2.7M) and Stempoint Capital LP ($1.9M).
- Company
- Effector Therapeutics Inc.
- CUSIP
- 28202V207
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 16 | $11.7M |
| Exits | 0 | $0 |
Ownership 15 holders
| Armistice Capital, LLC | 0.09% | New | 223,000 | $3.2M |
| Carlyle Group Inc. | 0.17% | New | 192,884 | $2.7M |
| Stempoint Capital LP | 0.51% | New | 132,793 | $1.9M |
| Sectoral Asset Management Inc. | 0.54% | New | 95,305 | $1.4M |
| Vanguard Group Inc. | 0.00% | New | 92,465 | $1.3M |
| Ensign Peak Advisors, Inc | 0.00% | New | 32,945 | $474K |
| Geode Capital Management, LLC | 0.00% | New | 22,609 | $325K |
| Raymond James & Associates | 0.00% | New | 12,345 | $178K |
| Sea Otter Advisors LLC | 1.06% | New | 10,557 | $152K |
| Morgan Stanley | 0.00% | New | 1,615 | $23K |
| Tower Research Capital LLC (TRC) | 0.00% | New | 1,534 | $22K |
| Royal Bank of Canada | 0.00% | New | 432 | $6K |
| ICA Group Wealth Management, LLC | 0.00% | New | 247 | $4K |
| Wells Fargo & Company | 0.00% | New | 19 | $273 |
| Qube Research & Technologies Ltd | 0.00% | New | 3 | $43 |
"% of holder's portfolio" is EFTR's weight in each manager's 13F, not the share of Effector Therapeutics Inc. the manager owns.